Sugammadex Versus Neostigmine for Reversal of Rocuronium Neuromuscular Block in Patients Having Catheter-based Neurointerventional Procedures

Trial Profile

Sugammadex Versus Neostigmine for Reversal of Rocuronium Neuromuscular Block in Patients Having Catheter-based Neurointerventional Procedures

Not yet recruiting
Phase of Trial: Phase IV

Latest Information Update: 21 Nov 2017

At a glance

  • Drugs Sugammadex (Primary) ; Glycopyrrolate; Neostigmine
  • Indications Neuromuscular blockade
  • Focus Therapeutic Use
  • Most Recent Events

    • 13 Nov 2017 Planned initiation date changed from 1 Nov 2017 to 14 Nov 2017.
    • 01 Nov 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top